[go: up one dir, main page]

KR960700742A - 아토피성질환 치료약(atopic disease remedy) - Google Patents

아토피성질환 치료약(atopic disease remedy) Download PDF

Info

Publication number
KR960700742A
KR960700742A KR1019950704026A KR19950704026A KR960700742A KR 960700742 A KR960700742 A KR 960700742A KR 1019950704026 A KR1019950704026 A KR 1019950704026A KR 19950704026 A KR19950704026 A KR 19950704026A KR 960700742 A KR960700742 A KR 960700742A
Authority
KR
South Korea
Prior art keywords
atopic
drug
interferon
atopic disease
atopic diseases
Prior art date
Application number
KR1019950704026A
Other languages
English (en)
Other versions
KR100278351B1 (ko
Inventor
시로오 이이노
요시하루 카와시마
Original Assignee
마에다 카쯔노수케
토오레 카부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마에다 카쯔노수케, 토오레 카부시키가이샤 filed Critical 마에다 카쯔노수케
Publication of KR960700742A publication Critical patent/KR960700742A/ko
Application granted granted Critical
Publication of KR100278351B1 publication Critical patent/KR100278351B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Birds (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

인터페론 β를 유효성분으로 하는 아토피성질환 치료약이다. 본 발명의 치료약은, 아토피성 피부염의 피부증상을 유의하게 개선하고, 알레르기반응의 산생요인인 혈중 호산구수를 분명하게 감소시키며, 또한 효과가 빠르고 지속성이 있으므로, 아토피성질환 치료약으로서 유용하다.

Description

아토피성질환 치료약(ATOPIC DISEASE REMEDY)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 인터페론 β를 유효성분으로 하는 아토피성질환 치료약.
  2. 제1항에 있어서, 인터페론 β가 천연형인 아토피성질환 치료약
  3. 제1항에 있어서, 인터페론 β 및 약리학적으로 허용되는 담체를 혼합한 의약조성물로 이루어지는 아토피성 질환 치료약
  4. 제1항에 있어서, 아토피성질환이 아토피성 피부염 또는 아토피성 천식인 아토피성질환 치료약
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950704026A 1994-01-28 1994-01-28 아토피성질환 치료약 KR100278351B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1994/000124 WO1995020395A1 (fr) 1994-01-28 1994-01-28 Medicament contre des maladies atopiques

Publications (2)

Publication Number Publication Date
KR960700742A true KR960700742A (ko) 1996-02-24
KR100278351B1 KR100278351B1 (ko) 2001-01-15

Family

ID=14098153

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950704026A KR100278351B1 (ko) 1994-01-28 1994-01-28 아토피성질환 치료약

Country Status (6)

Country Link
US (1) US5709853A (ko)
EP (1) EP0694307B1 (ko)
JP (1) JP3269125B2 (ko)
KR (1) KR100278351B1 (ko)
DE (1) DE69427970T2 (ko)
WO (1) WO1995020395A1 (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69434777T2 (de) * 1993-07-27 2007-06-14 Mario Bigazzi Verwendung von Relaxin zur Herstellung von therapeutischer Mittel
JP3269125B2 (ja) * 1994-01-28 2002-03-25 東レ株式会社 アトピー性皮膚炎治療薬
US6121247A (en) * 1996-03-29 2000-09-19 The Johns Hopkins University Therapy for allergic diseases
JP3845915B2 (ja) * 1996-10-31 2006-11-15 東レ株式会社 ネコのアトピー性皮膚炎治療剤および治療方法
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
EP1487494A2 (en) * 2002-02-26 2004-12-22 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US20160250097A9 (en) * 2004-03-25 2016-09-01 The Feinstein Institute For Medical Research Treatment of inflammation by non-invasive stimulation
WO2005092308A2 (en) * 2004-03-25 2005-10-06 The Feinstein Institute For Medical Research Neural tourniquet
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
DE602005025020D1 (de) 2004-12-27 2011-01-05 The Feinstein Inst Medical Res Behandlung von entzündlichen erkrankungen durch el
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
DK2107920T3 (da) 2007-01-29 2013-10-21 Univ Fraser Simon Transvaskulært nervestimulationsapparat
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9211409B2 (en) * 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US20090275997A1 (en) * 2008-05-01 2009-11-05 Michael Allen Faltys Vagus nerve stimulation electrodes and methods of use
CN102215909B (zh) * 2008-11-18 2014-09-10 赛博恩特医疗器械公司 优化用于消炎刺激的电极放置的装置和方法
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
AU2010258792B2 (en) 2009-06-09 2015-07-02 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2011079309A2 (en) 2009-12-23 2011-06-30 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
DE102011052816A1 (de) * 2011-08-18 2013-02-21 Tigo Gmbh Verwendung von Interferon-beta zur Behandlung von Alopecia areata
EP3556427B1 (en) 2012-03-05 2022-06-08 Lungpacer Medical Inc. Transvascular nerve stimulation apparatus
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
JP6359528B2 (ja) 2012-06-21 2018-07-18 ラングペーサー メディカル インコーポレイテッドＬｕｎｇｐａｃｅｒ Ｍｅｄｉｃａｌ Ｉｎｃ． 経血管横隔膜ペーシング・システム及び使用方法
CN105873630B (zh) 2013-11-22 2020-01-03 隆佩瑟尔医疗公司 用于通过经血管神经刺激辅助呼吸的装置和方法
CA2935454A1 (en) 2014-01-21 2015-07-30 Simon Fraser University Systems and related methods for optimization of multi-electrode nerve pacing
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US10293164B2 (en) 2017-05-26 2019-05-21 Lungpacer Medical Inc. Apparatus and methods for assisted breathing by transvascular nerve stimulation
EP3645107B1 (en) 2017-06-30 2022-08-31 Lungpacer Medical Inc. Systems for prevention, moderation, and/or treatment of cognitive injury
US10195429B1 (en) 2017-08-02 2019-02-05 Lungpacer Medical Inc. Systems and methods for intravascular catheter positioning and/or nerve stimulation
US10940308B2 (en) 2017-08-04 2021-03-09 Lungpacer Medical Inc. Systems and methods for trans-esophageal sympathetic ganglion recruitment
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US20190175908A1 (en) 2017-12-11 2019-06-13 Lungpacer Medical Inc. Systems and methods for strengthening a respiratory muscle
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
EP3877043A4 (en) 2018-11-08 2022-08-24 Lungpacer Medical Inc. STIMULATION SYSTEM AND ASSOCIATED USER INTERFACES
EP3968932A4 (en) 2019-05-16 2023-01-18 Lungpacer Medical Inc. SYSTEMS AND METHODS FOR DETECTION AND STIMULATION
WO2020252037A1 (en) 2019-06-12 2020-12-17 Lungpacer Medical Inc. Circuitry for medical stimulation systems
JP2023526080A (ja) 2020-05-21 2023-06-20 ザ・フェインステイン・インスティチュート・フォー・メディカル・リサーチ 迷走神経刺激のためのシステムおよび方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8522336D0 (en) * 1985-09-09 1985-10-16 Biogen Nv Composition for treatment of allergies
CA2069870E (en) * 1989-12-01 2005-01-11 Donald Y. M. Leung Treatment of atopic disorders with gamma-interferon
JP3269125B2 (ja) * 1994-01-28 2002-03-25 東レ株式会社 アトピー性皮膚炎治療薬

Also Published As

Publication number Publication date
JP3269125B2 (ja) 2002-03-25
EP0694307B1 (en) 2001-08-16
US5709853A (en) 1998-01-20
DE69427970T2 (de) 2001-11-29
KR100278351B1 (ko) 2001-01-15
EP0694307A4 (en) 1996-05-08
JPH0648957A (ja) 1994-02-22
WO1995020395A1 (fr) 1995-08-03
DE69427970D1 (de) 2001-09-20
EP0694307A1 (en) 1996-01-31

Similar Documents

Publication Publication Date Title
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
KR920019342A (ko) 골질환 치료제
EP1040830A4 (en) REMEDY FOR NEURODEGENERATIVE DISEASES
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
KR970705990A (ko) 피부 질환 치료용 조성물(Compositions for the Treatment of Skin Disorders)
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
FR2711140B1 (fr) 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
DK0945136T3 (da) Topisk lægemiddel indeholdende ciclosporin
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
ATE235901T1 (de) Pharmazeutische zusammensetzung enthaltend 3-(2,2,2-trimethylhydrazinium)proprionat und gamma- butyrobetain für die behandlung von herz-gefäss- erkrankungen
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
BR9812443A (pt) 1-2-3-4-5-6-hexahidro-2,6-metano-3-benzazocin-10-óis substituìdos, processos para sua preparação e seu emprego como medicamentos
DK1343472T3 (da) Thixotropisk næsespray
KR930019224A (ko) 유산 위험 치료제
ATE220922T1 (de) Konjugat aus einem wirkstoff, einem polyether und ggf. einem nicht als körperfremd angesehenen, nativen protein
BR0115881A (pt) Emprego de compostos ciclohexanona substituìdos de 6-dimetilaminometil-1-fenil para a terapia da incontinência urinária
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
ATE258229T1 (de) Substanz fa-70d, herstellungsverfahren und verwendungen
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19950921

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19981229

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20000727

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20001018

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20001019

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20040710